Evotec SE ADR Dossier - Source-backed chat

Evotec SE ADR

EVTFrankfurt Stock Exchange

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)1.17

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.65Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $584.6M

Enterprise Value $665.7M

Shares Outstanding 355.4M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Evotec SE is navigating a critical transition period in 2026 under its newly launched 'Project Horizon' business transformation. The company is shifting from a legacy, asset-heavy integrated model toward a leaner, capital-efficient, and sustainably profitable structure. While long-term growth prospects remain supported by its high-potential Just – Evotec Biologics segment and a strategic pivot toward AI-enabled drug discovery (highlighted by the appointment of Rui Wang as Head of Global In Silico & AI), near-term performance is heavily weighed down by restructuring execution risks, soft early-stage discovery demand, and significant profitability pressures. Q1 2026 results showed a steep 21.7% year-over-year revenue decline to €156.6 million and a negative adjusted Group EBITDA of €21.9 million. Although the company's liquidity remains solid at €444.8 million (bolstered by a €116.1 million convertible bond placement and expected proceeds from the Tubulis stake sale), a 'Hold' recommendation is warranted until structural cost savings materialize and the core Discovery segment stabilizes.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.01

Mean target$3.83

High · most bullish analyst$6.88

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

In the bear case, Evotec faces severe execution delays and higher-than-expected cash restructuring costs under Project Horizon. Early-stage drug discovery demand remains structurally depressed, and high customer concentration (where the top ten customers represent over 60% of revenue) leads to significant contract losses. Just – Evotec Biologics fails to secure new partners, leaving its heavy manufacturing footprint underutilized. Full-year 2026 revenues and adjusted EBITDA miss the low end of guidance, forcing further dilutive capital raises or debt restructuring, and driving the stock down to new multi-year lows.

Base CaseCentral scenario

In the base case, Evotec successfully executes its Project Horizon restructuring, achieving its targeted €75 million in annual run-rate savings by the end of 2027, with 20-30% materializing in 2026. The core Discovery & Preclinical Development segment stabilizes in the second half of 2026 as biotech funding conditions improve, while Just – Evotec Biologics continues to scale through its asset-light technology licensing model. Full-year 2026 revenues land within the guided range of €700 million to €780 million, and adjusted Group EBITDA recovers to positive territory, meeting the €0 million to €40 million guidance. Valuation multiples re-rate moderately as execution risks subside.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong long-term growth potential of the Just – Evotec Biologics segment, driven by its highly productive, asset-light technology enablement model and validation from major partners like Sandoz.
Significant cost-reduction potential from Project Horizon, which targets €75 million in structural annual savings by 2027 through footprint optimization and workforce adjustments.
Strategic focus on high-margin, AI-enabled, and in silico drug discovery capabilities, reinforced by the high-profile appointment of former AstraZeneca AI lead Rui Wang.
Solid liquidity cushion of €444.8 million as of Q1 2026, further supported by the successful €116.1 million convertible bond placement and expected cash proceeds from the Tubulis stake sale to Gilead.

Key Investment Risks

High execution risk associated with the complex Project Horizon restructuring, including the closure of four global sites and the layoff of up to 800 employees.
Persistent softness and cyclical volatility in the early-stage drug discovery market, which led to a 15% revenue decline in the D&PD segment in Q1 2026.
High customer concentration, with the top ten customers historically accounting for over 60% of total revenues, exposing the company to significant single-client risk.
Near-term profitability pressures, as evidenced by the negative adjusted Group EBITDA of €21.9 million and a net loss of €121.9 million in Q1 2026.

Thesis Invalidation Triggers

Failure to meet the full-year 2026 financial guidance of €700 million to €780 million in revenue and €0 million to €40 million in adjusted EBITDA.
Significant delays or cost overruns in the implementation of Project Horizon, or failure to realize the targeted 20-30% of savings in fiscal year 2026.
Loss of a major strategic partner or a material reduction in order volumes from top-tier pharmaceutical clients.
Further material weaknesses identified in internal controls over financial reporting that lead to restatements or loss of investor confidence.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.